According to latest survey conducted by pipelinereview.com, Epoetin alfa (Epogen/ESPO/Procrit/Eprex) marketed by Amgen, Kirin & Johnson & Johnson mainly used in renal and cancer anaemia remains number one top selling biological drug for the year 2007 with the annual sale of about US$ 5,764 million compared to US$ 6,024 million last year(2006).
Recently clinical trial studies done on anti-anemic drugs, marketed by Amgen and Johnson & Johnson revels increase risk of death among the cancer patients. The conflict is that whether the higher risk of death is due to blood clots or drug which is a synthetic form of a natural hormone called erythropoietin directly stimulates the growth and spread of tumor.